Citation Report
List of articles citing

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia

DOI: 10.1016/j.eururo.2009.04.033
European Urology, 2009, 56, 727-35.

Source: https://exaly.com/paper-pdf/47048921/citation-report.pdf
Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
67	Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. *European Urology*, **2009**, 56, 735-6	10.2	
66	Words of wisdom. Re: Biological, clinical, and ethical advances of placebo effects. *European Urology*, **2010**, 58, 792-3	10.2	
65	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. *Drug Design, Development and Therapy*, **2010**, 4, 159-71	4.4	23
64	Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. *Urology*, **2010**, 75, 1452-8	1.6	51
63	Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. *Yearbook of Urology*, **2010**, 2010, 217-218		
62	Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. *Urology*, **2011**, 77, 123-9	1.6	42
61	Current world literature. *Current Opinion in Urology*, **2011**, 21, 84-91	2.8	
60	An algorithm for medical management in male lower urinary tract symptoms. *Current Opinion in Urology*, **2011**, 21, 5-12	2.8	33
59	Benign prostate hyperplasia: a review of the year's progress from bench to clinic. *Current Opinion in Urology*, **2011**, 21, 22-6	2.8	51
58	Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. *BJU International*, **2011**, 107, 1104-9	5.6	34
57	Outline of JUA clinical guidelines for benign prostatic hyperplasia. *International Journal of Urology*, **2011**, 18, 741-56	2.3	52
56	JUA clinical guidelines for benign prostatic hyperplasia. *International Journal of Urology*, **2011**, 18, e1-e33	2.3	4
55	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. *British Journal of Clinical Pharmacology*, **2011**, 72, 197-204	3.8	43
54	A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. *Journal of Sexual Medicine*, **2011**, 8, 2617-24	1.1	20
53	Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. *European Urology*, **2011**, 60, 1105-13	10.2	135
52	Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities. *European Urology*, **2011**, 60, 1205-6	10.2	7
51	Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E135-40	5.6	29

50	The recent phosphodiesterase type 5 inhibitors. *Human Andrology*, **2012**, 2, 57-64	1	
49	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. *Drugs and Aging*, **2012**, 29, 771-81	4.7	8
48	Evaluation and Medical Management of BPH and LUTS in Men. **2012**, 55-65		
47	A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with Ⅱblockers for lower urinary tract symptoms due to benign prostatic hyperplasia. *European Urology*, **2012**, 61, 994-1003	10.2	212
46	Reply to Jin-Qiu Yuan, Zu-Yao Yang, and Chen MaoⅢ Letter to the Editor re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A Systematic Review and Meta-Analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with Ⅱ-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol 2012;61:994Ⅱ1003. *European Urology*, **2012**, 62, e36-e38	10.2	
45	Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. *Journal of Sexual Medicine*, **2012**, 9, 271-81	1.1	98
44	Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. *Urologia Internationalis*, **2013**, 91, 10-8	1.9	28
43	The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Current Urology Reports*, **2013**, 14, 585-94	2.9	17
42	SOP conservative (medical and mechanical) treatment of erectile dysfunction. *Journal of Sexual Medicine*, **2013**, 10, 130-71	1.1	117
41	Rapid analysis of tadalafil in human blood plasma and seminal plasma by liquid chromatography/tandem mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, **2013**, 77, 149-57	3.5	16
40	Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multicenter, double-blind, placebo controlled trial. *Journal of Urology*, **2013**, 189, 1006-13	2.5	20
39	Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. *International Journal of Urology*, **2013**, 20, 28-39	2.3	43
38	Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. *BJU International*, **2013**, 112, 990-7	5.6	38
37	EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *European Urology*, **2013**, 64, 118-40	10.2	808
36	The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. *Research and Reports in Urology*, **2013**, 5, 99-111	1.3	15
35	BPH/LUTS and ED: common pharmacological pathways for a common treatment. *Journal of Sexual Medicine*, **2013**, 10, 2382-93	1.1	20
34	A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. *Therapeutic Advances in Urology*, **2014**, 6, 135-47	3.2	28
33	Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: a human in vivo study. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 307, H888-94	5.2	16

32	Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. *International Journal of Endocrinology*, **2014**, 2014, 329456	2.7	77
31	The Use of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. **2014**, 113-128		
30	A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. *Journal of Sexual Medicine*, **2014**, 11, 187-96	1.1	51
29	Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial--treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. *Urology*, **2014**, 84, 51-6	1.6	26
28	Evaluation and management of male lower urinary tract symptoms: treatment patterns and guidelines in a correlation study among Polish urology consultants. *Archives of Medical Science*, **2015**, 11, 1340-51	2.9	1
27	Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review. *Arab Journal of Urology Arab Association of Urology*, **2015**, 13, 155-61	1.7	9
26	Korean clinical practice guideline for benign prostatic hyperplasia. *Investigative and Clinical Urology*, **2016**, 57, 30-44	1.9	27
25	Antimuscarinics, β3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm. *Urologic Clinics of North America*, **2016**, 43, 337-49	2.9	3
24	Benign prostatic hyperplasia. *Nature Reviews Disease Primers*, **2016**, 2, 16031	51.1	132
23	Effect of short- and long-term sildenafil treatment on erectile dysfunction in rats with partial bladder outlet obstruction. *Neurourology and Urodynamics*, **2016**, 35, 108-14	2.3	2
22	Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial. *Urology*, **2017**, 100, 59-64	1.6	22
21	Emerging drugs for the treatment of benign prostatic hyperplasia. *Expert Opinion on Emerging Drugs*, **2017**, 22, 201-212	3.7	11
20	The protective effect of L-arginine, tadalafil, and their combination in rat testes after ischemia and reperfusion injury. *Canadian Urological Association Journal*, **2017**, 11, E19-E25	1.2	13
19	Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. *LUTS: Lower Urinary Tract Symptoms*, **2018**, 10, 84-92	1.9	17
18	Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). *LUTS: Lower Urinary Tract Symptoms*, **2018**, 10, 76-83	1.9	4
17	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *The Cochrane Library*, **2018**, 11, CD010060	5.2	8
16	Medical Therapy for Benign Prostatic Hyperplasia. **2018**, 9-22		
15	Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study. *Central European Journal of Urology*, **2019**, 72, 44-50	0.9	7

14	Tadalafil for the treatment of benign prostatic hyperplasia. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 929-937	4	12
13	Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. *Current Urology Reports*, **2020**, 21, 56	2.9	11
12	Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). *Urologia Internationalis*, **2020**, 104, 587-593	1.9	4
11	Current Pharmacologic Treatment of Lower Urinary Tract Symptoms. *Current Clinical Urology*, **2014**, 121-222		1
10	An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Asian Journal of Andrology*, **2011**, 13, 630-5	2.8	16
9	Epidemiology of erectile dysfunction: A cross-sectional web-based survey conducted in an Indonesian national referral hospital. *F1000Research*, 8, 817	3.6	2
8	Treatment of benign prostatic hyperplasia. *Revista Da Associação Médica Brasileira*, **2017**, 63, 95-99	1.4	3
7	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. *Asian Journal of Andrology*, **2016**, 18, 723-31	2.8	8
6	Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?. *World Journal of Nephrology*, **2015**, 4, 138-47	3.6	9
5	Drug interaction (28. combination with therapeutic drugs used to treat overactive bladder). *Okayama Igakkai Zasshi*, **2013**, 125, 259-262	0	
4	Efficacy and safety of oral pharmacological and supplementary therapies in bladder pain syndrome: a systematic review. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, **2022**, 58,	1.6	
3	Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms. *LUTS: Lower Urinary Tract Symptoms*,	1.9	1
2	Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-14		0
1	Neuroanatomy and Neurophysiology. **2022**, 1-22		0